Analyst Price Target is $6.63
▲ +92.03% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Antares Pharma in the last 3 months. The average price target is $6.63, with a high forecast of $7.00 and a low forecast of $5.50. The average price target represents a 92.03% upside from the last price of $3.45.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Antares Pharma. This Buy consensus rating has held steady for over two years.
Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.